This page shows the latest Lumykras news and features for those working in and with pharma, biotech and healthcare.
The National Institute for Health and Care Excellence (NICE) has issued a final appraisal document recommending Amgen’s Lumykras (sotorasib) for treatment use within the Cancer Drugs Fund. ... The CMA for Lumykras is based on clinical evidence from the
The European Commission (EC) has granted conditional marketing approval for Amgen’s Lumykras/Lumakras (sotorasib) for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with the ... Administered as a once-daily oral
Lumakras – known as Lumykras in the UK – will be available to 600 lung cancer patients in England through an early access scheme. ... The drug – known as Lumakras in the US and Lumykras in the UK – will be available initially to treat 600
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.